Entrada Therapeutics, Inc. Common Stock
TRDAEntrada Therapeutics, Inc. is a biotechnology company focused on developing intracellular biologic therapies. Utilizing its proprietary platform, the company aims to create innovative treatments for diseases with high unmet medical needs by delivering therapeutic molecules directly into cells.
Company News
Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 2 of its ELEVATE-45-201 Phase 1/2 study at an increased dose of 10 mg/kg (up from 5 mg/kg in Cohort 1). The study evaluates ENTR-601-45 for treating Duchenne muscular dystrophy in exon 45 skipping amenable patients. The company remains...
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in l...
Law firm Holzer & Holzer is investigating whether Entrada Therapeutics complied with federal securities laws following disappointing topline results from its ELEVATE-44-201 Duchenne muscular dystrophy study. Cohort 1 showed a 2.36% increase in dystrophin, falling below analyst expectations and causing the stock price to decline. The firm is seeki...
The Schall Law Firm is investigating Entrada Therapeutics (NASDAQ: TRDA) for allegedly issuing false or misleading statements regarding Phase 1/2 clinical trial results. The company characterized topline data from the ELEVATE-44-201 study as 'positive,' but results showed only marginal protein production improvements, falling short of competitive...
Entrada Therapeutics reported progress across its RNA-based therapeutic pipeline, with multiple clinical programs in development for Duchenne muscular dystrophy (DMD) and expansion into ocular diseases. The company expects to report data from ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026, initiate a Phase 1/2 study for ENTR-601-50 by e...
